source
- EU regulator backs Novo's hemophilia A preventive therapy and recommends seven additional drugsThe European Medicines Agency's human medicines committee issued a positive opinion on Novo's preventive treatment for hemophilia A, indicating it meets the agency's standards for further developme…
- Novo Nordisk acquires three early-stage obesity programs from KallyopeNovo Nordisk announced the purchase of three early-stage obesity drug programs from New York‑based biotech Kallyope, expanding its metabolic pipeline. The acquired assets are not GLP‑1 incretins.…